Brief: Lava Therapeutics Announces FDA IND Clearance For Lava-051 For Treatment Of Hematologic Malignancies
12/05/2022 12:04
May 12 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS ANNOUNCES FDA IND CLEARANCE FOR LAVA-051
FOR
TREATMENT OF HEMATOLOGIC MALIGNANCIES
Source text for Eikon: ID:nGNX4Nw6V4
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM